Alnylam Pharmaceuticals (ALNY) EBT (2009 - 2026)
Alnylam Pharmaceuticals' (ALNY) quarterly EBT came in at $177.8 million in Q2 2026, up 530.43% YoY from $28.2 million in Q2 2025, and down 19.78% on a QoQ basis from $221.7 million in Q1 2026.
Alnylam Pharmaceuticals (ALNY) EBT (2009 - 2026) Analysis & Trends
Alnylam Pharmaceuticals (ALNY) has 18 years of EBT data on file, last reported at $177.8 million in Q2 2026.
- Quarterly EBT rose 530.43% year-over-year to $177.8 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $766.3 million (up 321.28% YoY) and the FY2025 annual result came in at $323.2 million, up 185.63% from the prior year.
- EBT fell to $177.8 million in Q2 2026, from $221.7 million in the prior quarter.
- In the past five years, EBT ranged from a high of $280.6 million in Q3 2025 to a low of -$405.9 million in Q3 2022.
- A 5-year average of -$67.5 million and a median of -$86.1 million in 2024 frame the typical range for EBT.
- Annual changes were most pronounced in 2025 — EBT sank 269.92% — and 2026, when it jumped 9460.35%.
- Tracing ALNY's EBT over 5 years: stood at -$207.0 million in 2022, then soared by 33.49% to -$137.7 million in 2023, then plunged by 40.87% to -$194.0 million in 2024, then jumped by 144.47% to $86.3 million in 2025, then surged by 106.13% to $177.8 million in 2026.
- The last three EBT figures came in at $177.8 million (Q2 2026), $221.7 million (Q1 2026), and $86.3 million (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.39 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.53 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 541.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 312.46 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2,828.29 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 177.81 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -11.37 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | -294.56 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 177.81 Mn |
| Mar 31, 2026 | 221.65 Mn |
| Dec 31, 2025 | 86.26 Mn |
| Sep 30, 2025 | 280.57 Mn |
| Jun 30, 2025 | -35.36 Mn |
| Mar 31, 2025 | -2.37 Mn |
| Dec 31, 2024 | -193.96 Mn |
| Sep 30, 2024 | -108.66 Mn |
| Jun 30, 2024 | -11.17 Mn |
| Mar 31, 2024 | -63.59 Mn |
| Dec 31, 2023 | -137.69 Mn |
| Sep 30, 2023 | 150.74 Mn |
| Jun 30, 2023 | -274.21 Mn |
| Mar 31, 2023 | -172.36 Mn |
| Dec 31, 2022 | -207.02 Mn |
| Sep 30, 2022 | -405.94 Mn |
| Jun 30, 2022 | -274.67 Mn |
| Mar 31, 2022 | -239.36 Mn |
| Dec 31, 2021 | -260.30 Mn |
| Sep 30, 2021 | -204.24 Mn |